Propylthiouracil-Induced Autoimmune Syndromes: Two Distinct Clinical Presentations with Different Course and Management

Seminars in Arthritis and Rheumatism

Volumn 36, Issue 1, 2006, Pages 4-9

  Aloush, Valerie ^a   Litinsky, Irina ^a   Caspi, Dan ^a   Elkayam, Ori ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

ANA; ANCA; lupus; propythiouracil; vasculitis

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOPHOSPHAMIDE; DNA ANTIBODY; HISTONE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; STEROID;

ADULT; ANTIBODY DETECTION; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; COMPARATIVE STUDY; CONVALESCENCE; DELAYED DIAGNOSIS; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; JOINT SWELLING; KIDNEY DISEASE; LUNG DISEASE; LUPUS LIKE SYNDROME; MEDICAL LITERATURE; MEDLINE; MORNING STIFFNESS; MUSCULOSKELETAL DISEASE; MYALGIA; OUTCOME ASSESSMENT; PAPULOVESICULAR RASH; PLASMAPHERESIS; PLEURISY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEROLOGY; SKIN MANIFESTATION; STEROID THERAPY; SYNOVITIS; THORAX PAIN; TREATMENT DURATION; VASCULITIS; WEAKNESS;

ADULT; ANTITHYROID AGENTS; FEMALE; GRAVES DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROPYLTHIOURACIL; TREATMENT OUTCOME; VASCULITIS, HYPERSENSITIVITY; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS; WITHHOLDING TREATMENT;

EID: 33746646799     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2006.03.003     Document Type: Article

References (49)

1. Shiran A., Schechnerb C., and Dickstein G. Propylthiouracil-induced agranulocytosis in four patients previously treated with the drug. JAMA 22 266 (1991) 3129-3130
2. Aksoy M., and Erdem S. Aplastic anemia after propylthiouracil. Lancet 7556 1 (1968) 1379
3. Liaw Y.-F., Huan M.J., Fank D., Li K.L., Wu S.S., and Chen T.J. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. a cohort study. Ann Intern Med 6 118 (1993) 424-428
4. Miyazono K., Okasaki T., Uchida S., Totsuka Y., Matsumoto T., Ogata E., et al. Propylthiouracil-induced diffuse interstitial pneumonitis. Arch Intern Med 144 9 (1984) 1764-1765
5. Wing S.S., and Fantus I.G. Adverse immunologic effects of antithyroid drugs. CMAJ 136 2 (1987) 121-127
6. Takuwa N., Kojima I., and Ogata E. Lupus-like syndrome-a rare complication in thionamide treatment for Graves' disease. Endocrinol Jpn 28 5 (1981) 663-667
7. Vasily D.B., and Tyler W.B. Propylthiouracil-induced cutaneous vasculitis. Case presentation and review of the literature. JAMA 243 5 (1980) 458-461
8. Olsen N.J. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 18 5 (2004) 677-688
9. Hess E. Drug-related lupus. N Engl J Med 318 22 (1988) 1460-1462
10. Herlin T., Birkebaek N.H., Wolthers O.D., Heegaard N.H., and Wiik A. Anti-neutrophil cytoplasmic autoantibody (ANCA) profiles in propylthiouracil-induced lupus-like manifestations in monozygotic triplets with hyperthyroidism. Scand J Rheumatol 31 1 (2002) 46-49
11. Cambridge G., Wallace H., Bernstein R.M., and Leaker B. Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Br J Rheumatol 33 2 (1994) 109-114
12. Kudoh Y., Kuroda S., Shimamoto K., and Iimura O. Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies. Clin Nephrol 48 1 (1997) 41-43
13. Vogt B.A., Kim Y., Jennette J.C., Falk R.J., Burke B.A., and Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 124 6 (1994) 986-988
14. Ohtsuka M., Yamashita Y., Doi M., and Hasegawa S. Propylthiouracil-induced alveolar haemorrhage associated with antineutrophil cytoplasmic antibody. Eur Respir J 10 6 (1997) 1405-1407
15. Dolman K.M., Gans R.O., Vervaat T.J., Zevenbergen G., Maingay D., Nikkels R.E., et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 342 8872 (1993) 651-652
16. Kitahara T., Hiromura K., Maezawa A., Ono K., Narabara N., Yano S., et al. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA). review of literature. Clin Nephrol 47 5 (1997) 336-340
17. Yuasa S., Hashimoto M., Yura T., Sumikura T., Takahashi N., Shoji T., et al. Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy. Nephron 73 4 (1996) 701-703
18. D'Cruz D., Chesser A.M., Lightowler C., Comer M., Hurst M.J., Baker L.R., et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol 34 11 (1995) 1090-1091
19. Tanemoto M., Miyakawa H., Hanai J., Yago M., Kitaoka M., and Uchida S. Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease. report of three adult cases. Am J Kidney Dis 26 5 (1995) 774-780
20. Harper L., and Savage C.O. Case of propylthiouracil-induced ANCA associated small vessel vasculitis. Nephrol Dial Transplant 13 2 (1998) 455-458
21. Pillinger M., and Staud R. Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. Semin Arthritis Rheum 28 2 (1998) 124-129
22. Gunton J.E., Stiel J., Caterson R.J., and Mc Elduff A. Anti-Thyroid Drugs and Antineurophil Cytoplasmic Antibody Positive Vasculitis. A Case Report and Review of the Literature. J Clin Endocrinol Metab 84 1 (1999) 13-16
23. Dhillon S.S., Singh D., Doe N., Oadri A.M., Ricciardi S., and Schwarz M.I. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 116 5 (1999) 1485-1488
24. Otsuka S., Kinebuchi A., Tabata H., Yamakage A., and Yamakasi S. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis following propylthiouracil therapy. Br J Dermatol 142 4 (2000) 828-830
25. Ligier S., Pham C.D., Watters A.K., Kassis J., and Fortin P.R. Purpura fulminans and anticardiolipin antibodies in a patient with Grave's disease. Scand J Rheumatol 31 6 (2002) 371-373
26. Poomthavorn P., Mahachaklertwattana P., Tapaneya-Olarn W., Chuansumrit A., and Chunharas A. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy. report of 2 children with Graves' disease. J Med Assoc Thai 85 Suppl 4 (2002) S1295-S1301
27. Nakamori Y., Tominaga T., Inoue Y., and Shinohara K. Propylthiouracil (PTU)-induced vasculitis associated with antineutrophil antibody against myeloperoxidase (MPO-ANCA). Intern Med 42 6 (2003) 529-533
28. Jacobs E.M., Hartkamp A., and Kaasjager H.A. PTU-associated cutaneous vasculitis with ANCA anti-MPO and anti-PR3 antibodies. Neth J Med 61 9 (2003) 296-299
29. Ohwada R., Kato K., Ohmori K., Isozaki O., Hotta M., Ono M., et al. A man with interstitial pneumonia due to propylthiouracil. A man with interstitial pneumonia due to propylthiouracil 42 10 (2003) 1026-1030
30. Yamauchi K., Sata M., Machiya J., Osaka D., Wada T., and Abe S. Antineutrophil cytoplasmic antibody positive alveolar haemorrhage during propylthiouracil therapy for hyperthyroidism. Respirology 8 4 (2003) 532-535
31. Winters M.J., Hurley R.M., and Lirenman D.S. ANCA-positive glomerulonephritis and IgA nephropathy in a patient on propylthiouracil. Pediatr Nephrol 17 4 (2002) 257-260
32. Mathieu E., Fain O., Sitbon M., and Thomas M. Systemic adverse effect of antithyroid drugs. Clin Rheumatol 18 1 (1999) 66-68
33. Erten Y., Bodur H., Sahiner S., Tolunay O., Akkaya V., Canbakan B., et al. Antineutrophil cytoplasmic antibody associated vasculitis and rapidly progressive glomerulonephritis as a complication of propylthiouracil therapy. Clin Endocrinol 57 5 (2002) 699-700
34. Helfgott S.M., and Smith R.N. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2002. A 21-year-old man with arthritis during treatment for hyperthyroidism. N Engl J Med 347 2 (2002) 122-130
35. Yamada A., Sato K., Hara M., Tochimoto A., Takagi S., Hizuka N., et al. Propylthiouracil-induced lupus-like syndrome developing in a Graves' patient with a sibling with systemic lupus erythematosus. Intern Med 41 12 (2002) 1204-1208
36. Prasad G.V., Bastacky S., and Johnson J.P. Propylthiouracil-induced diffuse proliferative lupus nephritis. review of immunological complications. J Am Soc Nephrol 8 7 (1997) 1205-1210
37. Berkman E.M., Orlin J.B., and Wolfsdorf J. An anti-neutrophil antibody associated with a propylthiouracil-induced lupus-like syndrome. Transfusion 23 2 (1983) 135-138
38. Weetman A.P. Non-thyroid autoantibodies in autoimmune thyroid disease. Best Pract Res Clin Endocrinol Metab 19 1 (2005) 17-32
39. Short A.K., and Lockwood C.M. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM 88 11 (1995) 775-783
40. Elkayam O., Yaron M., and Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis 55 10 (1996) 769-771
41. Karpinski J., Jotty S.S., Radoux V., Levy M., and Baran D. D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature. Am J Nephrol 17 6 (1997) 528-532
42. Nassberger L., Sjoholm A.G., Jonsson H., Sturfelt G., and Akesson A. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 81 3 (1990) 380-383
43. Elkayam O., Yaron M., and Caspi D. Minocycline-induced autoimmune syndromes. an overview. Semin Arthritis Rheum 28 6 (1999) 392-397
44. Nassberger L., Johansson A.C., Bjorck S., and Sjoholm A.G. Antibodies to neutrophil granulocyte myeloperoxidase and elastase. autoimmune responses in glomerulonephritis due to hydralazine treatment. J Intern Med 229 3 (1991) 261-265
45. Choi H.K., Merkel P.A., Walker A.M., and Niles J.L. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis. prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43 2 (2000) 405-413
46. Gunton J.E., Stiel J., Clifton-Bligh P., Wilmshurst E., and McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 142 6 (2000) 587
47. Gao Y., Zhao M.H., Guo X.H., Xin G., Gao Y., and Wang H.Y. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res 30 2 (2004) 205-213
48. Jiang X., Khursigara G., and Rubin R.L. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266 5186 (1994) 810-813
49. Waldhauser L., and Uetrecht J. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Toxicology 114 2 (1996) 155-162